FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior expanded …
Press Release
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients …
Akari Therapeutics to Participate in Two September Virtual Investor Conferences
NEW YORK and LONDON, September 10, 2020 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Participate in Two September Virtual Investor Conferences
Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress
International clinical development program of nomacopan for the potential treatment of COVID-19 pneumonia announcedPivotal Phase III study in patients with …
Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia
Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and BrazilProposed multi-center U.S. randomized clinical …
